Red light therapy (RLT) is sold with the promise that it warms up your blood flow and floods your tissues with nitric oxide, a molecule that relaxes blood vessels. The mechanism is real and well documented in lab studies, but the clinical evidence in living people is thinner and messier than most marketing suggests. This article walks through what the science actually shows, where it falls apart, and who might reasonably expect a benefit.
What "circulation" and "nitric oxide" actually mean here
Two separate ideas get blended together in red light therapy marketing, so it helps to pull them apart.
Circulation is the movement of blood through your vessels. When people say RLT "boosts circulation," they usually mean one of two things: more blood flowing through the tiny vessels near the skin's surface (microcirculation), or wider, more relaxed arteries that carry more blood overall (vasodilation). These are measurable. Researchers track them with laser Doppler imaging, thermal cameras, and ultrasound.
Nitric oxide (NO) is a short-lived gas your body makes on purpose. It is one of the main signals that tells the smooth muscle wrapped around your blood vessels to relax. When that muscle relaxes, the vessel widens, and more blood flows through. NO is the bridge between the two ideas: the leading theory says red light frees up nitric oxide, and the freed nitric oxide is what widens your vessels.
That chain of logic is the heart of every "RLT improves circulation" claim. The rest of this article tests each link in the chain.
The mechanism: how light might move nitric oxide
Red and near-infrared light fall in a wavelength range, roughly 600 to 1,100 nanometers (nm), where they can pass through skin and reach the mitochondria inside your cells. Inside the mitochondria sits an enzyme called cytochrome c oxidase (CCO), the last stop in the chain that makes cellular energy (ATP). CCO absorbs light strongly in exactly this red and near-infrared band. That overlap is why these specific wavelengths get used.
Here is the part that involves nitric oxide. When a cell is stressed or starved of oxygen, nitric oxide can bind to CCO and clog it, slowing energy production. The dominant hypothesis, laid out in a 2020 evidence review, is that red light photo-dissociates that bound NO, knocking it loose from the enzyme (What Lies at the Heart of Photobiomodulation, 2020). Two things are supposed to happen at once:
- CCO unclogs, so the cell makes more energy.
- The freed nitric oxide drifts into the surrounding tissue, where it relaxes nearby blood vessels and increases blood flow.
There is a second proposed route. Beyond simply releasing trapped NO, light may push your cells to make fresh nitric oxide. A 2023 review in the journal Nitric Oxide describes how near-infrared light can boost the activity of endothelial nitric oxide synthase (eNOS), the enzyme in vessel walls that produces NO (Photobiomodulation and nitric oxide signaling, 2023). The same review notes light may also release NO from storage molecules called nitrosothiols, and may help convert nitrite into usable NO using heme proteins like hemoglobin.
So the mechanism is not one pathway. It is several overlapping ones. That is a strength (multiple ways to reach the same result) and a weakness (it is hard to pin down which one matters in a real person, and hard to dose for).
The biphasic dose problem
A crucial and under-advertised detail: more light is not better. Photobiomodulation follows a biphasic dose response. Low doses stimulate; high doses do nothing or actively inhibit. Push the dose past the sweet spot and the benefit shrinks, disappears, or reverses. This is why a longer session or a more powerful panel can leave you worse off than a moderate one, and why the "optimal" dose in the lab is a narrow window, not a floor you keep climbing.
The biphasic curve also explains a lot of the messy human results you will read about below. Two studies can use the "same" red light and reach opposite conclusions because one happened to land in the effective window and the other overshot or undershot it. Distance from the skin, panel power, session length, and how long you treat all change the delivered dose. A panel held six inches away delivers a very different dose than one held two feet away, even for the same number of minutes. When marketing brags about raw power output, remember that more power is only better up to a point, and past that point it works against you.
The evidence, graded honestly
This is where the story gets complicated. The mechanism is solid in cells and in animals. In living humans, the circulation results are inconsistent, and the cleanest study found that plain red light did not work while near-infrared did.
Animal and lab evidence (moderate to strong, but indirect)
The mechanistic case is best supported here. In a controlled mouse study, researchers shone 670 nm red light on a hind limb and measured blood flow directly with laser Doppler imaging. A 5-to-10-minute treatment over a small area produced clear vasodilation, and 14 days of repeated treatment steadily increased perfusion in a limb whose blood flow had been restricted (In Vivo Characterization of a Red Light-Activated Vasodilation, 2022). The effect tracked with a nitric-oxide-related vasoactive species, which is exactly what the mechanism predicts.
A 2024 animal study went further on the nitric oxide link. Using 808 nm infrared light after a simulated stroke, researchers showed the treatment increased eNOS activity and protected blood vessels, and the benefit vanished when they chemically blocked eNOS (Photobiomodulation Inhibits Ischemia-Induced Brain Endothelial Senescence via eNOS, Antioxidants, 2024). Blocking the enzyme and watching the effect disappear is strong evidence that nitric oxide is genuinely doing the work, at least in mice.
The honest caveat: animals are not people, and a controlled hind limb or a stroke model is not the same as a tired human shining a panel on their back at home.
Human evidence (mixed and often null for red light)
The single most informative human trial here is also the most inconvenient for red light marketing. In a randomized controlled study, 20 healthy non-smokers had either 633 nm red light or 830 nm near-infrared light applied to the wrist for five minutes (Microcirculatory Response to Photobiomodulation, Lasers in Surgery and Medicine, 2020). The results:
- Near-infrared (830 nm) raised microcirculatory blood flow by about 27%, climbing to roughly 54% over a 20-minute follow-up.
- Red light (633 nm) did not raise median blood flow at all.
On top of that, only half the participants responded even to the near-infrared light. The responders had skin temperatures between 33 and 37.5°C. People with "hot" hands (above 37.5°C) or "cold" hands (below 33°C) did not respond. So the effect was wavelength-dependent and depended on your starting state. That is a big asterisk on any blanket "RLT increases circulation" claim.
A separate double-blind randomized study looked at LED light during chronic wound healing in diabetic and non-diabetic patients and tracked blood microcirculation as part of the outcome (Effect of LED on blood microcirculation during chronic wound healing, Lasers in Medical Science, 2017). Wound and circulation research like this is more encouraging, but it studies sick tissue with poor baseline flow, not healthy people looking for a general boost.
There is a logical reason damaged or poorly perfused tissue might respond better than a healthy limb. The whole nitric-oxide-from-CCO mechanism depends on there being trapped, inhibitory nitric oxide to release in the first place. Stressed, low-oxygen tissue tends to have more of that clogged-up CCO, so there is more for the light to free. A healthy, well-oxygenated hand may simply have little to gain because nothing is jammed. That is a tidy explanation, and it fits the pattern in the data, but it is still partly hypothesis. It has not been nailed down head-to-head in humans, so treat it as a reasonable theory rather than a settled fact.
It is also worth being clear about what these human studies do not show. None of them demonstrate a lasting change in whole-body circulation, a drop in blood pressure that holds up over weeks, or any benefit for diagnosed cardiovascular disease. The measured effects are local (the patch of skin or tissue under the light) and short (minutes to perhaps an hour). Anyone selling RLT as a systemic cardiovascular tool is reaching well past what the human evidence supports.
Performance and recovery evidence (weak to modest)
Some of the "circulation" sales pitch leans on exercise: better blood flow means more oxygen to muscles and faster recovery. The meta-analyses are lukewarm. A systematic review and meta-analysis of photobiomodulation for muscular performance and fatigue in healthy people found some benefit for endurance and repetitions, but rated the evidence quality from very low to moderate (PBM for muscular performance and fatigue, meta-analysis, 2018). A 2025 systematic review on whole-body photobiomodulation was even less encouraging: across the five small studies it found, whole-body light showed no clear benefit for exercise performance or recovery (the one positive signal was better sleep quality) (Whole-body photobiomodulation for exercise performance and recovery, 2025).
Worth naming plainly: a meaningful slice of device and performance research is funded or run by people with a commercial stake, and many trials are small, short, and unblinded. Treat dramatic before-and-after claims with skepticism. The improvements that survive rigorous, blinded testing are real but modest.
Evidence summary table
| Claim | Strength of evidence | What the data actually show | Biggest caveat |
|---|---|---|---|
| Red/NIR light releases nitric oxide from cells | Strong (lab) | CCO releases bound NO; eNOS activity rises | Mostly cells and animals |
| NIR light increases skin microcirculation | Moderate (human) | ~27-54% flow increase with 830 nm | Only ~50% of people responded |
| Plain red light (633 nm) increases microcirculation | Weak / null | No median flow increase in RCT | Wavelength matters more than "red" branding |
| Improves blood flow in damaged/poorly perfused tissue | Moderate | Helps wound healing, some flow gains | Studied in sick tissue, not healthy users |
| Boosts athletic recovery via circulation | Weak to modest | Small effects on fatigue, endurance | Low-quality, often industry-linked trials |
| Treats cardiovascular disease (PAD, hypertension) | Insufficient | No solid human RCT evidence | Do not use as a substitute for medical care |
Red light vs near-infrared: the wavelength split
If you take one practical lesson from the human data, make it this: for circulation, the wavelength matters, and near-infrared has the better track record than visible red.
Visible red light (around 630-660 nm) penetrates only a few millimeters. It reaches the skin and shallow tissue. That is fine for surface concerns, but the one clean head-to-head human trial showed 633 nm doing nothing for blood flow.
Near-infrared (around 808-850 nm) reaches deeper, into muscle and the small vessels below the skin. That depth is likely why the 830 nm arm of the trial moved blood flow and the red arm did not. Most quality devices marketed for circulation combine both bands, often 660 nm plus 850 nm. For a deeper breakdown of which wavelengths do what, see our guide on red light therapy wavelengths explained and the broader science of photobiomodulation.
| Wavelength band | Typical range | Penetration depth | Circulation evidence | Best matched use |
|---|---|---|---|---|
| Visible red | 630-660 nm | A few mm (skin) | Weak/null in one RCT | Surface skin, shallow tissue |
| Near-infrared (NIR-I) | 800-850 nm | Up to several cm | Moderate (flow gains shown) | Muscle, deeper vessels, circulation |
| NIR-II (emerging) | 1000-1300 nm | Deepest | Early animal data only | Research, not consumer devices yet |
How circulation claims compare to the alternatives
Red light therapy is not the only way to nudge blood flow, and several alternatives have stronger or cheaper evidence.
Exercise is the single most proven circulation intervention there is. Walking, especially for people with poor leg circulation, has decades of randomized trial support and improves vessel function through the same nitric oxide pathway, just driven by the physical force of blood moving against vessel walls. Nothing in the RLT literature comes close to that evidence base.
Heat (saunas, warm baths, infrared saunas) reliably dilates surface vessels and raises skin blood flow. Part of what some RLT devices deliver is simply gentle heating; FDA-cleared infrared lamps are literally cleared as heating devices (more on that below). If your goal is warm, flushed skin, heat does that directly. Compare the two in our piece on red light therapy vs infrared sauna.
Dietary nitrate (beetroot juice, leafy greens) raises nitric oxide through the diet-nitrate-nitrite-NO pathway, with reasonable human trial support for blood pressure and exercise. It is cheap and works through chemistry RLT only partly mimics.
Where RLT may have a niche is convenience and combining effects: it can plausibly nudge local blood flow while also doing other things (pain modulation, tissue repair) in the same session. But on circulation alone, it is not the strongest tool in the box. If pain or recovery is your real target, see red light therapy for pain relief and red light therapy for athletes.
What the FDA actually allows brands to say
This trips people up constantly. Many infrared therapy devices hold FDA 510(k) clearance, and circulation is part of that clearance, but in a narrow, specific way.
Infrared lamps are commonly cleared "to provide topical heating for the purpose of elevating tissue temperature for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm, relieving stiffness, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation." You can confirm a device's exact wording by searching the FDA 510(k) database.
Read that carefully. The cleared claim is temporary and local increase in blood circulation, tied to heating. It is not a claim to treat cardiovascular disease, improve whole-body circulation, lower blood pressure, or reverse poor circulation from diabetes or artery disease. FDA clearance also means "substantially equivalent to an existing device," not "proven to work in rigorous trials." A device can be legally cleared and still have weak efficacy data behind the broader marketing claims wrapped around it.
So when a panel's box says "increases circulation," that is the modest, heating-based, temporary, local claim talking. The bigger promises in the ad copy are usually not part of the clearance.
Safety and who should be cautious
For most healthy adults, red and near-infrared light therapy is low-risk when used as directed. The most common issues are mild: temporary skin warmth, redness, or eye strain from looking at the light. Eye protection matters, especially with near-infrared, because you cannot see NIR and your blink reflex will not protect you. See our full rundown of red light therapy side effects.
Because we are specifically talking about circulation and nitric oxide, a few groups deserve extra caution:
- People on photosensitizing medications (some antibiotics, retinoids, certain diuretics and others) can react more strongly to light. Check with a pharmacist.
- Pregnancy: limited data, especially over the abdomen. Get medical clearance.
- Active cancer or suspicious skin lesions in the treatment area: avoid, since the therapy changes mitochondrial activity and blood flow in the tissue.
- People with circulation-affecting conditions like diabetes, peripheral artery disease, or neuropathy: reduced sensation means you may not feel overheating, and these are serious conditions that need real medical management, not a panel. Some early research is encouraging for diabetic nerve and wound problems (see red light therapy for diabetic neuropathy), but that is adjunct care under a doctor, not a replacement.
- Bleeding disorders or fresh wounds in the area: be cautious, since increased local blood flow is the whole point.
The honest bottom line on safety: the therapy is gentle, but "gentle" is not the same as "do whatever you want." More is not better, and circulation problems are rarely something to self-treat.
Who it's reasonably for
Putting the evidence together, here is a sober read on who might get something out of RLT for circulation:
- Someone wanting a mild, temporary, local blood flow boost (warm, slightly flushed skin in a treated area) using a near-infrared or red-plus-NIR device. The FDA-cleared, heating-based claim covers this, and the human data partly support it for NIR.
- Athletes stacking it with other recovery who treat the circulation effect as a small bonus, not the main event. The performance data are modest at best.
- People with damaged or poorly perfused tissue (wounds, certain nerve issues) as an adjunct under medical supervision, where the evidence is comparatively stronger.
And who it is probably not for, at least not as a circulation fix: anyone with diagnosed cardiovascular disease hoping to skip real treatment, anyone expecting whole-body or lasting circulation changes, and anyone with "cold hands" expecting a guaranteed response, since the one good RCT found those folks often did not respond at all.
RLT for circulation sits in an awkward middle. The mechanism is genuine and elegant. The human payoff is small, wavelength-dependent, and inconsistent. Set your expectations there and you will not be disappointed.
Frequently Asked Questions
Does red light therapy actually increase nitric oxide in the body?
In cells and animals, yes, fairly convincingly. Light can release nitric oxide bound to cytochrome c oxidase and can raise the activity of eNOS, the enzyme that makes NO in blood vessel walls (Photobiomodulation and nitric oxide signaling, 2023). In living humans, the downstream effect (more blood flow) shows up for near-infrared light but was absent for plain red light in the cleanest controlled trial.
Is near-infrared or red light better for circulation?
Near-infrared has the better evidence. In a head-to-head randomized study, 830 nm near-infrared raised skin blood flow 27-54%, while 633 nm red light produced no median increase (Microcirculatory Response to Photobiomodulation, 2020). Near-infrared also penetrates deeper, reaching muscle and the small vessels below the skin. Devices labeled "red light" that include an 850 nm band are the ones with a circulation rationale.
How long do the blood flow effects last?
Short-lived. In human studies, the increase in microcirculation builds during and shortly after a session and is measured over roughly a 20-minute follow-up window. The FDA clearance language itself describes only a "temporary" and "local" increase in circulation. There is no good evidence of lasting, whole-body circulation change from light alone.
Can red light therapy treat poor circulation from diabetes or artery disease?
Not as a standalone treatment, and you should not rely on it for that. Poor circulation from diabetes or peripheral artery disease is a serious medical problem. Some early research on wound healing and diabetic nerve issues is encouraging as adjunct care (LED and blood microcirculation in wound healing, 2017), but that means alongside proper medical management, never instead of it.
Why didn't I feel anything? Is the device broken?
Maybe not. Even in a controlled study using a known-good near-infrared light, only about half of healthy participants responded with a measurable blood flow increase. Response depended on baseline skin temperature, with "hot" and "cold" hands often not responding (Microcirculatory Response to Photobiomodulation, 2020). Individual variation is real, and a quiet response does not necessarily mean the device failed.
Medical disclaimer: This article is for general information only and is not medical advice. Red light therapy is not a treatment for cardiovascular disease or any circulatory condition. Talk to a qualified healthcare provider before starting any new therapy, especially if you have a heart condition, diabetes, circulation problems, are pregnant, or take photosensitizing medication.